TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19798460

Group type: EXPERIMENTAL
Intervention: Arzoxifene 5, 10, 20, or 40 mg
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 and 40 mg
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Arzoxifene
Number of subjects: 219

Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 18061146

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy during the follicular phase
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Proton magnetic resonance spectroscopy during the luteal phase
Number of subjects: 25

Group type: COMPARATOR
Intervention: Healthy control subjects (HCs) during the luteal phase
Number of subjects: 25
Study: 16177941

Group type: EXPERIMENTAL
Intervention: Telemonitoring of multiple vital parameters (weight, blood pressure, heart rate and rhythm, oxygen saturation, respiration rate)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Telemonitoring with outpatient treatment based on findings
Number of subjects: 24
Study: 12948983

Group type: EXPERIMENTAL
Intervention: Moving to low-poverty neighborhoods
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Moving to less poor neighborhoods (Boys)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Remaining in high-poverty neighborhoods (Parents)
Number of subjects: 550

Group type: COMPARATOR
Intervention: Staying in public housing (Boys)
Number of subjects: 550
Study: 10945137

Group type: EXPERIMENTAL
Intervention: Emotional imagery
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Verbalization
Number of subjects: 54

Group type: COMPARATOR
Intervention: No processing instructions (Control)
Number of subjects: 54
Study: 8888375

Group type: EXPERIMENTAL
Intervention: ondansetron (16 mg PO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study: 1893810

Group type: EXPERIMENTAL
Intervention: Cisapride 30 mg rectally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6408673

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methylphenidate 5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (0 mg of both diazepam and methylphenidate)
Number of subjects: 0
Study: 30873676

Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg for 5 days)
Number of subjects: 632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 632

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 632
Study: 29365057

Group type: EXPERIMENTAL
Intervention: Drug Repositioning Recommendation System (DRRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case studies for selected drugs using DRRS
Number of subjects: 0
Study: 26731191

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (CTX) discontinuation
Number of subjects: 500
Study: 23128818

Group type: EXPERIMENTAL
Intervention: Remifentanil (rPCA) - 20 µg boluses using PCA pump with a lockout interval of 3 min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Epidural analgesia (EA) - 0.125% bupivacaine with sufentanil 0.5 µg/mL in top‐up boluses every hour until delivery
Number of subjects: 12
Study: 22431960

Group type: EXPERIMENTAL
Intervention: Higher 3-day accumulated diuretic doses after dialysis initiation
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Higher time-varying 3-day accumulative diuretic doses
Number of subjects: 572
Study: 19340731

Group type: EXPERIMENTAL
Intervention: Preoperative administration of omeprazole
Number of subjects: 155

Group type: COMPARATOR
Intervention: Postoperative administration of omeprazole
Number of subjects: 155
Study: 17601908

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Social conflict
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Composite score of three or more high-risk responses
Number of subjects: 1047

Group type: EXPERIMENTAL
Intervention: Interpersonal risk factors assessment
Number of subjects: 1047
Study: 15116081

Group type: EXPERIMENTAL
Intervention: Nutritional counselling intervention
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation (Control)
Number of subjects: 98
Study: 12078599

Group type: EXPERIMENTAL
Intervention: Exposed dental implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Submerged dental implants
Number of subjects: 10
Study: 9739606

Group type: EXPERIMENTAL
Intervention: HTA projects
Number of subjects: 0
Study: 8584545

Group type: EXPERIMENTAL
Intervention: Inpatient teaching program
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postdischarge telephone follow‐up program
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postdischarge group teaching program
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Inpatient teaching protocol focusing on 'survival skills' for self‐care management postdischarge
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Patients with longer lengths of stay and more vessels bypassed
Number of subjects: 90
Study: 2501817

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg TRH
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg TRH
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 843096

Group type: EXPERIMENTAL
Intervention: Corn oil-in-water emulsion (5, 10, 15, or 30 gm doses containing 250 mg of microsize griseofulvin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultramicrosize drug tablets (two 125 mg tablets dispersed in polyethylene glycol 6000)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial microsize griseofulvin tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Corn oil (10 gm dose of emulsion)
Number of subjects: 0
Study: 31994598

Group type: COMPARATOR
Intervention: High-viscosity GIC (Ketac Molar®)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Low-cost GIC (Vitro Molar®)
Number of subjects: 243
Study: 30973493

Group type: EXPERIMENTAL
Intervention: PITC (Patients' Intensive Telephone-Based Care Program)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control (usual care only)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Patients without depression at month 12
Number of subjects: 224
Study: 28555204

Group type: EXPERIMENTAL
Intervention: Fixed-on-2 implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed-on-4 implants
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25933807

Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules (OAR) by ED residents
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Bernese ankle rule (BAR) by ED residents
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ottawa ankle rules (OAR) by triage nurses
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Bernese ankle rule (BAR) by triage nurses
Number of subjects: 203

Group type: COMPARATOR
Intervention: Ottawa ankle rules (OAR)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Bernese ankle rule (BAR)
Number of subjects: 203
Study: 23936348

Group type: EXPERIMENTAL
Intervention: Sorafenib, carboplatin and paclitaxel (SCP)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 263
Study: 21457973

Group type: EXPERIMENTAL
Intervention: Letrozole (5mg from day 3 to day 7 of menses for 6 consecutive cycles)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 140
Study: 19508323

Group type: EXPERIMENTAL
Intervention: Kestose (1 to 2 g daily for 12 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (maltose, 1 to 2 g daily for 12 weeks)
Number of subjects: 29
Study: 17148967

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day increasing to 1000 mg twice a day after 2 weeks) with rosiglitazone placebo (Met/P, N = 26)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) with metformin placebo (Rosi/P, N = 27)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) plus metformin (500 mg twice a day increasing to 1000 mg twice a day after 2 weeks; Met/Rosi, N = 25)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Dual placebo (P/P, N = 27)
Number of subjects: 105
Study: 15471552

Group type: EXPERIMENTAL
Intervention: Valvular calcification score 5
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no valvular calcification)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Valvular calcification score 1
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Valvular calcification score 2
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Valvular calcification score 4
Number of subjects: 102
Study: 11287371

Group type: EXPERIMENTAL
Intervention: COP treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control antigens (tuberculin-purified protein or tetanus toxoid)
Number of subjects: 60
Study: 9100581

Group type: EXPERIMENTAL
Intervention: Canrenoate (2 x 200 mg, administered at 0800 and 1700 h before the experimental night)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Canrenoate
Number of subjects: 9
Study: 8171171

Group type: EXPERIMENTAL
Intervention: Structured group therapy plus fluoxetine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Structured group therapy plus placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (therapy plus fluoxetine and therapy plus placebo)
Number of subjects: 20
Study: 3390394

Group type: EXPERIMENTAL
Intervention: Logynon (ethinyl oestradiol and Levonorgestrol, n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: SHD 415G (Schering U.K., n = 12)
Number of subjects: 26
Study: 31771081

Group type: EXPERIMENTAL
Intervention: Antibiotics plus 500 mg/kg/day of IVIG for 7 days (Group II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antibiotics (Group I)
Number of subjects: 0
Study: 31100563

Group type: EXPERIMENTAL
Intervention: Lokomat, balneo‐physiotherapy, and Cerebrolysin (Group I)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lokomat associated with balneo‐physiotherapy (Group II)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Balneo‐physiotherapy alone (Group III, Control group)
Number of subjects: 70
Study: 28297813

Group type: EXPERIMENTAL
Intervention: Early non-sedation protocol (n=35)
Number of subjects: 70
Study: 26395094

Group type: EXPERIMENTAL
Intervention: Total Nasal Block (TNB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Central Facial Block (CFB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 23393157

Group type: EXPERIMENTAL
Intervention: Rare de novo or inherited hemizygous microdeletions overlapping exons of GPHN at chromosome 14q23.3
Number of subjects: 6
Study: 22014698

Group type: EXPERIMENTAL
Intervention: Vertical suture configuration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Horizontal suture configuration
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 18257738

Group type: COMPARATOR
Intervention: Standard PCNL with nephrostomy tube placement postoperatively
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL with antegrade placement of a Double‐J stent without nephrostomy
Number of subjects: 202
Study: 16329138

Group type: EXPERIMENTAL
Intervention: Ixabepilone with estramustine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: First-line PSA decline ≥ 50% with ixabepilone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: No first-line PSA decline ≥ 50% with ixabepilone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Discontinued first-line ixabepilone for disease progression
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Discontinued first-line ixabepilone for toxicity or patient preference
Number of subjects: 49
Study: 12793617

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11018687

Group type: EXPERIMENTAL
Intervention: cTnI
Number of subjects: 1130

Group type: EXPERIMENTAL
Intervention: cTnT
Number of subjects: 1130
Study: 8770026

Group type: COMPARATOR
Intervention: Methylprednisolone (METH) intravenous infusion (125 mg/30 min) during weight maintenance diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methylprednisolone (METH) oral therapy (40 mg/day) after 4 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Methylprednisolone (METH) oral therapy (40 mg/day) after 4 days during ad libitum food intake
Number of subjects: 20
Study: 1576625

Group type: EXPERIMENTAL
Intervention: Loracarbef 200 mg twice daily
Number of subjects: 319

Group type: COMPARATOR
Intervention: Cefaclor 250 mg thrice daily
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 319

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 319
Study: 3903079

Group type: EXPERIMENTAL
Intervention: Direct sibling contact (experimental group, N = 23 in Phase I, N = 33 in Phase II)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No direct sibling contact (control group, N = 21 in Phase I, N = 33 in Phase II)
Number of subjects: 66
Study: 30170853

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin I (hs-cTnI) assay
Number of subjects: 48282
Study: 27121401

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 187

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 187
Study: 24149749

Group type: COMPARATOR
Intervention: 5-minute rest in temperate environment (5Temp)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30-minute rest in cold environment (30Cold)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5-minute rest in cold environment (5Cold)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 30-minute rest in temperate environment (30Temp)
Number of subjects: 10
Study: 23043189

Group type: EXPERIMENTAL
Intervention: ALN+VitD
Number of subjects: 140

Group type: COMPARATOR
Intervention: ALN
Number of subjects: 140
Study: 20395358

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Nicotine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo (C)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Varenicline (VP)
Number of subjects: 114
Study: 17279846

Group type: EXPERIMENTAL
Intervention: Trustworthiness
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Cooperativeness
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Other characteristics (e.g., intelligence)
Number of subjects: 3
Study: 16193688

Group type: EXPERIMENTAL
Intervention: Topical therapy with corticosteroids and nonsteroid antirheumatics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orally applied acetazolamide
Number of subjects: 0
Study: 11812705

Group type: EXPERIMENTAL
Intervention: N(2)O 67% with Sevoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: N(2)O 67% with Propofol
Number of subjects: 20
Study: 10624765

Group type: EXPERIMENTAL
Intervention: Bronchiectatic subjects
Number of subjects: 194

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Patients with acid regurgitation or upper abdominal distension
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Previous findings
Number of subjects: 194
Study: 7854539

Group type: EXPERIMENTAL
Intervention: Down's syndrome subjects
Number of subjects: 25
Study: 2167951

Group type: EXPERIMENTAL
Intervention: Single-dose dactinomycin (60 micrograms/kg)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Divided-dose dactinomycin (45 micrograms/kg)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Divided-dose dactinomycin (15 micrograms/kg per dose times five doses)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group (NWTS-3 unirradiated patients)
Number of subjects: 330
Study: 6794767

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 19

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 19
Study: 30885591

Group type: EXPERIMENTAL
Intervention: Ribaxamase (150 mg, four times per day during and for 72 hours after treatment with ceftriaxone)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo (given alongside ceftriaxone)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Ribaxamase
Number of subjects: 413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study: 29614467

Group type: EXPERIMENTAL
Intervention: Trunk motion visual feedback (VFB) during treadmill walking
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (stationary bulls-eye target)
Number of subjects: 40
Study: 27959607

Group type: EXPERIMENTAL
Intervention: Intravenous ustekinumab (130 mg or approximately 6 mg/kg)
Number of subjects: 1766

Group type: EXPERIMENTAL
Intervention: Subcutaneous ustekinumab (90 mg every 8 weeks or every 12 weeks)
Number of subjects: 1766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1766
Study: 25381593

Group type: EXPERIMENTAL
Intervention: Posterior foraminotomy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Anterior foraminotomy with fusion
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Core Outcome Measures Index
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Short Form-12 (SF-12) questionnaire
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Radiological outcomes
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Health economic outcomes
Number of subjects: 88
Study: 23158721

Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring of oculomotor nerve during surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Microsurgery without intraoperative monitoring
Number of subjects: 61
Study: 19279975

Group type: EXPERIMENTAL
Intervention: silver amalgam without zinc
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: white MTA‐Angelus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: white Portland cement (PC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vitremer
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: GC Fuji Ortho LC
Number of subjects: 50
Study: 17978866

Group type: EXPERIMENTAL
Intervention: Secondary back pain prevention program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive model including change variables
Number of subjects: 0
Study: 15890545

Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic foot and calf compression (IPC) for 3 hours per day for 6 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Supervised exercise for three hourly sessions per week for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Unsupervised exercise
Number of subjects: 34
Study: 11927519

Group type: EXPERIMENTAL
Intervention: Fasudil (300 microg/min for 15 minutes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intracoronary saline
Number of subjects: 20
Study: 10710774

Group type: EXPERIMENTAL
Intervention: Motor-timing tasks (self-paced and externally paced Sensorimotor Synchronization and Sensorimotor Anticipation)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Time-discrimination task
Number of subjects: 11
Study: 7725882

Group type: EXPERIMENTAL
Intervention: HE azeotrope
Number of subjects: 33

Group type: COMPARATOR
Intervention: Halothane anaesthesia (H)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Spinal anaesthesia with tetracaine (S)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: All groups (HE, H, S)
Number of subjects: 33
Study: 2209240

Group type: EXPERIMENTAL
Intervention: Chinese traditional medicine Xiao Chai Hu Tang (XCHT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: biphenyl dimethyl dicarboxylate (BDD)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: XCHT + BDD
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (without treatment)
Number of subjects: 86
Study: 7003449

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Naproxen 750mg daily
Number of subjects: 30
Study: 31108488

Group type: EXPERIMENTAL
Intervention: IMPULS treatment group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 28535549

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg (2 mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg (1 mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (2 mL) (Control group)
Number of subjects: 120
Study: 25886789

Group type: EXPERIMENTAL
Intervention: SR‐WBV 5 Hz, Noise 4/SR‐WBV 1 Hz, Noise 1
Number of subjects: 20

Group type: COMPARATOR
Intervention: SR‐WBV 1 Hz, Noise 1/SR‐WBV 5 Hz, Noise 1
Number of subjects: 20
Study: 24004237

Group type: EXPERIMENTAL
Intervention: Polymyxin B (6,000 U/kg IV)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (0.9% NaCl solution)
Number of subjects: 14
Study: 21461451

Group type: EXPERIMENTAL
Intervention: Music therapy sessions three times a week for 60 minutes
Number of subjects: 94

Group type: COMPARATOR
Intervention: Comparison group (no music therapy)
Number of subjects: 94
Study: 19477397

Group type: EXPERIMENTAL
Intervention: NT-proBNP assay and echocardiography
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: NT-proBNP assay
Number of subjects: 1012
Study: 17077439

Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 10827375

Group type: EXPERIMENTAL
Intervention: Enoxaparin plus aspirin
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Heparin plus aspirin
Number of subjects: 3171
Study: 8892117

Group type: EXPERIMENTAL
Intervention: Minority Academic Advising Program (MAAP)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (predominantly white nursing students)
Number of subjects: 114
Study: 2067506

Group type: EXPERIMENTAL
Intervention: Nifedipine sublingual 10 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 micrograms.kg‐1 i.v.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 36
Study: 6193349

Group type: EXPERIMENTAL
Intervention: Guanfacine once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Clonidine thrice daily
Number of subjects: 20
Study: 31565244

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg (dose escalated to 150 mg)
Number of subjects: 274